PO-0661: Gliosarcoma: prognostic and therapeutics factors  by Castelli, J. et al.
S308                                                                                                                                                    ESTRO 35 2016 
______________________________________________________________________________________________________ 
developments in imaging and technology may further improve 
the therapeutic index. 
 
PO-0659 
Impact of 68Ga-Dotatoc-PET on tumor delineation and 
outcome in patients with meningioma 
H. Fischer
1Technische Universität München TUM, Department of 
Radiation Oncology, München, Germany 
1, K. Kessel1,2, T. Pyka3, M. Devečka1, M. 
Schwaiger3, S.E. Combs1,2 
2Institute of Innovative Radiotherapy iRT, Helmholtz 
Zentrum München, München, Germany 
3Technische Universität München TUM, Department of 
Nuclear Medicine, München, Germany 
 
Purpose or Objective: Surgery represents the treatment of 
choice for meningiomas. However, complete resection is 
often not possible, and recurrence is common. Radiation 
therapy (RT) can be prescribed as an alternative treatment to 
surgery for low-grade meningiomas, or in the 
recurrent/adjuvant setting. Differentiation between normal 
tissue, i.e. meninges, post-operative changes and residual 
viable tumor can be difficult using MR and CT imaging alone. 
We evaluated the impact of 68Ga-Dotatoc-PET imaging on 
treatment planning including potential benefit in terms of 
outcome. 
 
Material and Methods: We analyzed 15 patients with WHO I 
meningiomas of different localizations. All patients were 
treated with fractionated stereotactic radiotherapy (FSRT) 
with a total dose of 54 Gy and a single dose of 1.8 Gy. An 
advanced radiation oncologist delineated gross tumor volume 
(GTV) independently once based on diagnostic CT and MRI 
only (GTV_MR/CT), and a second time complemented by data 
of diagnostic 68Ga-Dotatoc-PET (GTV_PET). For image fusion 
and target definition BrainLab iPlan RT® software (Munich, 
Germany) was used. The intersection and union volumes of 
both GTVs (GTV_inter, GTV_union), were calculated. 
 
Results: In 11 of 15 patients (73%) the additional data gained 
by 68Ga-Dotatoc-PET led to a lager GTV. In four patients 
(27%) GTV_PET was smaller than GTV_MR/CT. The mean 
intersection of both GTVs was 58.6%. Hence, 41.4% of the 
GTV_PET was contributed only due to information from 68Ga-
Dotatoc-PET. About 22.6% of the GTV_MR/CT was not 
delineated in the GTV_PET volume because no increased 
tracer enhancement could be detected in these parts. Our 
first analyses of overall and progression free survival showed 
no significance in patients with a 68Ga-Dotatoc-PET for 
tumor delineation during treatment planning. 
 
Conclusion: 68Ga-Dotatoc-PET improves the detection of 
residual or recurrent tumor cells especially in patients with 
meningioma of the skull base and the sphenoorbital region. In 
addition it helps to spare normal tissue in patients with large 
tissue defects after operation. However, the interobserver 
variability must be taken into account. The data will now be 
correlated with OS and further analyzed concerning the 
standard uptake values (SUV) of the PET-images to assess if a 
threshold value can be recommended for meningioma 
detection and delineation. 
 
PO-0660  
Evaluation of distant brain failure among patients 
undergoing SRS for melanoma brain metastases 
S. Kailas
1University of Central Florida, College of Medicine, Orlando, 
USA 
1, E. Kim1, A. Sarparast1, P. Adedoyin1, A. Keller1, G. 
Bhattal1, R. Ismail1, J. Babb1, T. Buntinx-Krieg1, J. Dajac1, T. 
Do1, Z. Pavlovic1, N. Ramakrishna2 
2UF Health Cancer Center-Orlando Health, Dept. of Radiation 
Oncology, Orlando, USA 
 
Purpose or Objective: The latency, overall extent, and rate, 
of distant brain failure for patients undergoing SRS for 
melanoma brain metastases is not well characterized. We 
evaluated the impact of multiple pre-treatment parameters 
including age, KPS, gender, extracranial disease status (ECD), 
initial number of metastases, initial aggregate tumor volume, 
and B-raf V600E status, on distant brain failure. We also 
evaluated the impact of WBRT performed before, combined 
with, or after SRS. 
 
Material and Methods: The retrospective study population 
included 54 melanoma patients with brain metastases treated 
with SRS between 11/2008 and 01/2014. The distant brain 
metastasis-free survival (DBMFS) was defined as latency in 
months from initial SRS to first subsequent radiographic 
evidence of new brain metastasis. The extent of overall 
distant brain failure (ODBF) was defined as the total number 
of new metastases that developed following initial SRS 
treatment. The distant brain failure rate (DBFR) was defined 
as the ODBF/RFI, where RFI was defined as the maximum 
radiographic follow-up interval in months. Kaplan Meir 
analysis was used to evaluate DBMFS and Log Rank test was 
used to determine the significance (p-value <0.05 was 
considered significant). For ODBF and DBFR, Independent 
sample t-test and one-way ANOVA were used for statistical 
evaluation. 
 
Results: The median overall DBMFS was 5.69 months. A 
significant difference in median DBMFS was observed for 
patients with KPS<70 vs KPS >70 (2.24 vs. 10.44 months, p 
<0.022). Females had significantly worse DBMFS than males 
(5.96 vs. 17.96 months, p<0.009). The initial number of 
metastases, total initial metastasis volume, ECD status, and 
B-raf V600E mutation status, were associated with no 
significant difference in DBMFS. The ODBF was also worse for 
females than males (P<0.002). The DBFR was worse for 
females (p<0.049), and those with c-kit mutation (P<0.024). 
WBRT had no significant effect on DBMFS, ODBF or DBFR in 
the study population. 
 
Conclusion: Characterization of the risk of distant brain 
failure is important to treatment selection, prognosis and 
follow-up. Among patients with melanoma brain metastases 
treated with SRS, our study found that female gender and a 
KPS<70 was associated with a significantly decreased latency 
to distant brain failure. In addition, female gender was 
associated with greater overall number of distant brain 
metastases and rate of distant brain failure. Mutations in c-
kit but not b-raf were found to be associated with increased 
distant brain failure. Further study is underway to examine 
the overall clinical prognostic relevance of these findings. 
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Purpose or Objective: In concern gliosarcoma management, 
the aims of this multicentre retrospective study were to 
identify prognostic or therapeutic factors impacting on 
overall survival. 
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Material and Methods: The analysis included all the patients 
treated for gliosarcoma between 1998 and 2014 in seven 
French academic centres. 
 
Results: Seventy-five patients with a median age of 60 years 
(range from 23 to 79 years) were treated with a combination 
of surgery (n=66), radiotherapy (adjuvant for 64 patients and 
exclusive for 8 patients) and temozolomide based 
chemotherapy (n=58). Median follow-up was 12 months 
(range from 2 to 71 months). Two-year overall survival (OS) 
and disease free survival rates were 12% (95% CI: 4-20%) and 
2% (95% IC: 0-6%), respectively. The median OS was 13 
months. Treatment at recurrence consisted of chemotherapy 
(n=38) (bevazicumab for 18 patients, resumed temozolomide 
for 10 patients), salvage surgery (n=8) and 
radiochemotherapy (n=1). In univariate analysis, younger 
age, high total dose of radiotherapy, long time to recurrence 
and treatment at recurrence increased significantly OS. In 
multivariate analysis, high total dose of radiotherapy (HR = 
0.97, p=0.007) and treatment at recurrence (HR=0.28 
p<0.001) were favourable prognostic factor of OS.  
 
Conclusion: High dose of radiotherapy and salvage surgery 
increase OS of gliosarcoma. 
 
Poster: Clinical track: Haematology  
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Purpose or Objective: JCOG0211 study demonstrated that 
the 5-year local control, 5-y OS and 5-y PFS of patients 
treated with RT-DeVIC were 94, 70 and 63%, respectively. 
NKEA project (UMIN000015491) conducted a multi-
institutional retrospective study to clarify the changing 
current practice of the treatment for Extranodal natural 
killer(NK)/T-cell lymphoma nasal type(ENKL) over the first 
decade of this century in Japan, reviewing detailed 
information on treatment, clinical features and prognosis of 
patients with ENKL. The aim of this sub-study is to 
investigate the relationship between local failure patterns 
and radiation therapy before and after JCOG0211 study. 
 
Material and Methods: Selection criteria of NKEA survey are 
newly pathologically diagnosed ENKL, any stage, and any type 
of treatment and treated from 2000 to 2013. From 32 
institutions, more than 384 data of patients with ENKL have 
been registering in the NKEA project database. Of them, 
radiation therapy (RT) data, focusing on CTV setting, of 233 
patients with localized nasal ENKL were evaluated with the 
JROSG-lymphoma committee. 
 
Results: The baseline patients characteristics were 
followings, median age was 58 years old (range 18-88), male 
dominant (2:1), stage I/II=162/66(2.4:1). The median dose of 
RT was 50 Gy (range 9-60), delivering median 25 (range 3-33) 
fractionation over 37 (range 9-106) days. The 3D-CRT (CT 
based RT planning) was applied in 88% of patients and IMRT in 
3%, using shrinking technique; 70%. RT was interrupted with 
15% of patients due to hematological and mucosal toxicities. 
After JCOG0211 study, 49% of RT was designed according to 
JCOG0211 RT protocol, while 80% or more were not 
compliant RT protocol before/during JCOG0211. The local 
control was 74% for all population, 88% of local control rate 
was observed in patients treated with RT compliant with 
JCOG0211 RT protocol (extended RT), while 70% in patients 
not compliant with JCOG RT protocol (small field/limited 
RT). Based on the results of RT-QA review; we would like 
proposed the CTV guideline for IMRT/VMAT. 
 
Conclusion: A multi-institutional retrospective survey after 
prospective clinical trial is important to review how the 
results of trial influence on the community standard practice 
of the treatment for rare lymphoma, and observance of 
radiation therapy guidance. The extended RT had higher local 
control rate than small limited RT. 
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Purpose or Objective: Primary thyroid lymphoma (PTL) is a 
relatively rare entity of extra-nodal lymphoma. There was no 
randomized clinical trial and the optimal treatment is not 
established. The purpose of this retrospective study is to 
verify the effectiveness and safety of our treatment protocol 
with long term follow-up.  
 
Material and Methods: The stage IE - IIE PTL patients treated 
with combined treatment including radiotherapy and 
followed up at least three years were eligible for this 
retrospective study. We used CHOP or CHOP-like regimens 
with or without rituximab. Chemotherapy was not 
administered to the patients who were IEA MALToma treated 
in or after 2007 or have a contraindication to it. Acute and 
late toxicities were graded by CTCAE v4.0. 
 
Results: Seventy-two PTL patients were analyzed and median 
follow-up period was 91 months (37 – 238 m) . The doses of 
radiotherapy were 36 - 61.2 Gy (median 41.4Gy). Seven-year 
overall survival and cause specific survival were 98.6 % and 
92.2 %, respectively. Recurrences were observed in 7 
patients; five of them were retreated (chemotherapy +/- 
radiotherapy) and four patients achieved complete remission. 
Three patients died during follow-up; 2 of them due to 
malignant lymphoma, one due to breast cancer. Grade 3 
dermatitis, mucositis and pneumonitis were observed in 11 
patients (15.2 %), 4 patients (5.5 %) and 3 patients (4.2 %), 
respectively. Two patients experienced grade 3 late toxicities 
(dyspnea and laryngeal edema), but we judged they were 
less relevant to the treatment. Laryngeal carcinomas which 
located in field of radiotherapy were appeared in two 
patients. 
 
Conclusion: Effectiveness and safety of our treatment 
protocol were excellent. Because PTL patients are expected 
to have long term survival, we should optimize our treatment 
strategy to minimize acute and late toxicities and patients’ 
quality of life. 
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